Palbociclib Intermediate CAS 1013916-37-4 Purity >99.0% (HPLC) Factory High Quality

Chemical Name: 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one  CAS: 1013916-37-4 Purity: >99.0% (HPLC)  Appearance: Faint Yellow Powder Intermediate of  of Palbociclib (CAS: 571190-30-2) High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Palbociclib Related Intermediates: Palbociclib CAS 571190-30-2 5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5 5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7 tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4
Item Specifications
Appearance Faint Yellow Powder
Purity / Analysis Method >99.0% (HPLC)  
Moisture (K.F) <0.50%
Residue on Ignition <0.20%
Total Impurities <1.00%
Test Standard Enterprise Standard
Usage Intermediate of Palbociclib (CAS: 571190-30-2)

Description:

Specifications:

Package & Storage:

Chemical Name 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one
Synonyms 2-Chloro-8-Cyclopentyl-5-Methylpyrido[2,3-d]pyrimidin-7(8H)-one; Palbociclib Intermediate 2
CAS Number 1013916-37-4
CAT Number RF-PI1847
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C13H14ClN3O
Molecular Weight 263.72
Water Solubility Slightly Soluble in Water
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

2-Chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (CAS: 1013916-37-4) is used as a pharmaceutical intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy by any organization, and as of December 2017 has been prescribed more than 90,000 times.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours